Inventor · disambiguated record
Martin B. Wax
Also filed as: WAX MARTIN B
18 granted patents·29 pending applications·225 citations·filing 1994–2024
94Inventor score
Top patents by PatentIndex Score
47 records- 0195US8632809B2Water insoluble polymer matrix for drug deliveryASGHARIAN BAHRAM·Filed 2007·Granted Jan 21, 2014·62 cites·15 claims
- 0293US7592324B2RNAi-mediated inhibition of ocular targetsALCON INC·Filed 2006·Granted Sep 22, 2009·26 cites·37 claims
- 0389US6814966B1Methods for treating glaucomaPHARMACIA CORP·Filed 2000·Granted Nov 9, 2004·37 cites·8 claims
- 0489US6531128B1Methods for treating glaucomaPHARMACIA CORP·Filed 2000·Granted Mar 11, 2003·36 cites·6 claims
- 0588US9446026B2Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2014·Granted Sep 20, 2016·8 cites·11 claims
- 0687US10183014B2Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2017·Granted Jan 22, 2019·2 cites·21 claims
- 0787US9814702B2Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2015·Granted Nov 14, 2017·2 cites·18 claims
- 0887US9623011B2Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2016·Granted Apr 18, 2017·2 cites·12 claims
- 0987US2024325357A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2024·Application pending·0 cites
- 1085US2024277674A1Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2023·Application pending·0 cites
- 1183US10307404B1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2018·Granted Jun 4, 2019·2 cites·37 claims
- 1278US10092549B2Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2014·Granted Oct 9, 2018·2 cites·20 claims
- 1378US9476047B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsARROWHEAD RES CORP·Filed 2015·Granted Oct 25, 2016·1 cites·13 claims
- 1475US5545626AMethod of treating glaucoma with oligonucleotidesUNIV COLUMBIA·Filed 1994·Granted Aug 13, 1996·45 cites·22 claims
- 1574US2021196690A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2021·Application pending·0 cites
- 1672US2021275501A1Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2020·Application pending·0 cites
- 1770US9173896B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsCHATTERTON JON E·Filed 2009·Granted Nov 3, 2015·0 cites·14 claims
- 1867US2019247368A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2019·Application pending·0 cites
- 1967US2019240201A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2019·Application pending·0 cites
- 2066US9139834B2RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesisARROWHEAD RES CORP·Filed 2014·Granted Sep 22, 2015·0 cites·17 claims
- 2166US2009036397A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMAALCON RES LTD·Filed 2008·Application pending·0 cites
- 2266US2009036396A1RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2008·Application pending·0 cites
- 2365US9752147B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 5, 2017·0 cites·21 claims
- 2465US2019314343A1Ocular formulations for drug-delivery and protection of the anterior segment of the eyePANOPTICA INC·Filed 2018·Application pending·0 cites
- 2564US2009326044A1RNAi-Mediated Inhibition of Ocular TargetsALCON RES LTD·Filed 2009·Application pending·0 cites
- 2662US2009098136A1Use of tnf receptor antagonists for treating dry eyeALCON RES LTD·Filed 2008·Application pending·0 cites
- 2761US2009117098A1Complement C1Q Inhibitors For The Prevention And Treatment Of GlaucomaALCON RES LTD·Filed 2008·Application pending·0 cites
- 2861US2009035225A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMAALCON RES LTD·Filed 2008·Application pending·0 cites
- 2960US9422556B2RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesisARROWHEAD RES CORP·Filed 2015·Granted Aug 23, 2016·0 cites·16 claims
- 3060US8754202B2RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesisCHATTERTON JON E·Filed 2011·Granted Jun 17, 2014·0 cites·1 claims
- 3160US2016354349A1Ocular formulations for drug-delivery to the posterior segment of the eyePANOPTICA INC·Filed 2016·Application pending·0 cites
- 3260US2016326533A1RNAi-Related Inhibition of TNF-alpha Signaling Pathway for Treatment of Ocular AngiogenesisARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3357US2011190376A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMAALCON RES LTD·Filed 2011·Application pending·0 cites
- 3457US2015057336A1RNAi-RELATED INHIBITION OF TNF alpha SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMAALCON RES LTD·Filed 2014·Application pending·0 cites
- 3556US2005119262A1Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agentPHARMACIA CORP·Filed 2004·Application pending·0 cites
- 3655US2010267811A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2010·Application pending·0 cites
- 3754US2010166676A1RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONSALCON RES LTD·Filed 2010·Application pending·0 cites
- 3854US2004213782A1Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressurePHARMACIA CORP·Filed 2004·Application pending·0 cites
- 3953US8865670B2RNAi-related inhibition of TNFα signaling pathway for treatment of glaucomaCHATTERTON JON E·Filed 2011·Granted Oct 21, 2014·0 cites·14 claims
- 4051US2009012030A1RNAi-MEDIATED INHIBITIN OF HTRA1 FOR TREATMENT OF MACULAR DEGENERATIONALCON RES LTD·Filed 2008·Application pending·0 cites
- 4150US2005032691A1Methods for treating glaucomaFiled 2004·Application pending·0 cites
- 4247US2008171719A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONSALCON MFG LTD·Filed 2007·Application pending·0 cites
- 4346US2009054365A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF OCULAR NEOVASCULARIZATIONALCON RES LTD·Filed 2008·Application pending·0 cites
- 4445US2011195962A1Use of multi-pharmacophore compounds to treat nasal disordersALCON RES LTD·Filed 2011·Application pending·0 cites
- 4544US2008214486A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF IOP-RELATED CONDITIONSALCON MFG LTD·Filed 2007·Application pending·0 cites
- 4643US2008194513A1RNAi-MEDIATED INHIBITION OF AQUAPORIN 4 FOR TREATMENT OF OCULAR NEOVASCULARIZATIONALCON RES LTD·Filed 2008·Application pending·0 cites
- 4724US2010226962A1Peri-corneal drug delivery deviceRODSTROM THERON R·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Martin B. Wax files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →